CAR-T and Immunocellular Therapies: A New Class of Medicines

Chimeric Antigen Receptor T-cell therapy (CAR-T) is an immunocellular therapy. This novel class of medicines, often referred to as Advanced Therapy Medicinal Products – ATMPs, are new and complex biological treatments. ATMPs can potentially transform the lives of patients who have treatment resistant blood cancers. As with most complex therapies, there can be serious and sometimes life-threatening complications to this novel and advanced technology. Every healthcare professional in contact with patients undergoing this treatment, both now and in the future, should be aware of immunocellular/ATMP therapy.

This exciting event, jointly hosted by RPS and King’s College Hospital, will equip you with knowledge, skills and confidence to be able to understand CAR-T / ATMP therapy and its place in clinical medicine, now and in the future.

Registration Details:  Event price £75 for RPS members and £145 for non-members.  Register via RPS website at https://events.rpharms.com/ereg/newreg.php?eventid=200197071&language=eng

Address of event: Royal Pharmaceutical Society, 66-68 East Smithfield, London, E1W 1AW

Deadline date for registration: N/A

Itinerary: See agenda at https://events.rpharms.com/website/993/home/agenda/